Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma

International Journal of Dermatology

Volumn 52, Issue 11, 2013, Pages 1445-1447

  Mir Bonafé, José M ^a   Cañueto, Javier ^b   Bravo, Javier ^a   De Unamuno, Pablo ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL VIRGEN DE LA CONCHA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; METHYLPREDNISOLONE ACEPONATE; SALICYLIC ACID; SUNITINIB;

ACTINIC KERATOSIS; AGED; ASTHMA; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LETTER; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PANCREAS METASTASIS; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KERATOSIS, ACTINIC; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; PANCREATIC NEOPLASMS; PYRROLES;

EID: 84886746944     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05265.x     Document Type: Letter

References (11)

1. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-1051.
2. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008; 58: 545-570.
3. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
4. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006; 368: 1329-1338.
5. Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003; 102: 795-801.
6. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896.
7. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
8. Brand D, Ackerman AB. Squamous cell carcinoma, not basal cell carcinoma, is the most common cancer in humans. J Am Acad Dermatol 2000; 42: 523-526.
9. Choong NW, Kozloff M, Taber D, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2010; 28: 677-683.
10. Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28: 21-28.
11. Goerner M, Seiwert TY, Sudhoff H. Molecular targeted therapies in head and neck cancer - an update of recent developments. Head Neck Oncol 2010; 2: 8.